This trialevaluates a new combination treatment for people with DLBCL that have failed a prior line of therapy.
- Non-Hodgkin's Lymphoma
1 Primary · 12 Secondary · Reporting Duration: Up to 2.5 years
Awards & Highlights
1 Treatment Group
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: R/R DLBCL · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2022. "A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05364424.
Frequently Asked Questions
What is the current cohort size of this research endeavor?
"The trial's sponsor, Hoffmann-La Roche, requires 40 patients that meet their inclusion criteria. These patients will be recruited from the New York University Langone Medical Center and UMASS Memorial Medical Center in Worcester." - Anonymous Online Contributor
What risks come with the progression of relapsed or refractory diffuse large B-cell lymphoma?
"The safety of R/R DLBCL has been assessed at a score of 1, as this is an early stage clinical trial with only restricted data that supports its efficacy and security." - Anonymous Online Contributor
Are participants being recruited to take part in this experiment?
"Clinicaltrials.gov indicates that this research study is actively recruiting participants; the trial was published on November 4th 2022 and revised for accuracy most recently on November 16th of the same year." - Anonymous Online Contributor